

To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Date: 14.08.2023

Unit: Decipher Labs Limited (Scrip Code-524752)

Sub: Outcome of Board Meeting for the quarter 30.06.2023 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Monday, the 14th day of August, 2023 at 5.00 P.M. at registered office of the Company for the quarter ended 30.06.2023 considered and approved the following:

1. Un- Audited Financial Results (standalone and consolidated) for the quarter ended 30.06.2023. **(Attached)**
2. Limited Review Report (standalone and consolidated) for the Quarter ended 30.06.2023. **(Attached)**
3. Appointment of M/s. S.S. Reddy & Associates, Company Secretaries as Secretarial Auditors for FY 2023-24.
4. Appointment of Mr. Sushant Mohan Lal as Internal Auditor for FY 2023-24.

The meeting concluded at 07:00 P.M.

This is for the information and records of the Exchanges, please.

Thanking you.

Yours Faithfully
For Decipher Labs Limited

Siva Kumar Reddy Chappidi
Company Secretary and Compliance Officer

Encl. as above

Annexure

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July13, 2023]

Particulars	Internal Auditor	Secretarial Auditors
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Mr. Sushant Mohan Lal as Internal Auditor of the company.	Appointment of M/s. S.S. Reddy Associates, Practicing Company Secretaries, as Secretarial Auditors of the Company.
Date of appointment & Terms of appointment	For the Financial Year 2023-24.	For the Financial Year 2023-24.
Brief Profile	Mr. Sushant Mohan Lal, He is an MBA from Kansas University, USA. He has been associated with the Company since long.	Mis. S.S. Reddy & Associates, established in the year 2007 by Mr. S. Sarveswara Reddy having wide client base ranging from Listed and Unlisted Companies in Infra and Real Estate, Defence, Software, Pharma etc., to Government Companies. Till date they have handled numerous corporate actions such as Initial Public Offers (IPOS), Takeovers, preferential issues, bonus issues, rights issues, buy back, mergers and demergers, delisting, revocation of suspension, corporate restructuring and so on.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable

DECIPHER LABS LIMITED. (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Statement of Standalone Financial Results For the Quarter Ended 30th June, 2023

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year ended
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	-	12.94	52.90	81.00
II. Other income	0.50	0.38	0.58	2.82
III. Total Income (I + II)	0.50	13.32	53.48	83.82
IV. Expenses				
Purchase of Stock in trade	-	10.35	31.50	47.25
Changes in inventories of stock in trade	-	4.42	-	4.42
Employee Benefits Expense	4.25	7.46	4.05	20.11
Finance Costs	-	-	-	-
Depreciation expense	0.36	1.36	1.47	5.74
Other expenses	6.44	23.63	12.01	46.03
Total expenses	11.05	47.22	49.02	123.55
V. Profit before Exceptional items (III - IV)	(10.55)	(33.91)	4.46	(39.74)
VI. Exceptional items	-	-	-	224.15
VII. Profit after Exceptional items (V - VI)	(10.55)	(33.91)	4.46	(263.89)
VIII. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	(1.67)	(2.62)	0.13	2.14
IX. Profit/(Loss) for the period (VII-VIII)	(12.22)	(36.53)	4.33	(261.75)
X. Other comprehensive income	-	-	-	-
XI. Total comprehensive income for the year	(12.22)	(36.53)	4.33	(261.75)
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share				
(1) Basic	(0.12)	(0.36)	0.04	(2.59)
(2) Diluted	(0.12)	(0.36)	0.04	(2.59)

Notes

1. The operations of the Group relate to two segments viz.; Manufacturing and Trading of Pharmaceutical drugs and Consultancy

Segment Information:

Particulars	Quarter ended			Year Ended
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Audited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	-	12.94	45.00	64.96
b) Consultancy Services	-	-	7.90	16.04
Total Sales	-	12.94	52.90	81.00
Less: Inter Segment Revenue	-	-	-	-
Total Revenue from Operations	-	12.94	52.90	81.00
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	(10.55)	(27.42)	3.80	28.70
b) Consultancy Services	-	(6.49)	0.67	7.09
Total	(10.55)	(33.91)	4.47	35.80
Less: Interest	-	-	-	-
Total Profit before tax	(10.55)	(33.91)	4.47	35.80
Capital employed (Segment assets - segment liabilities)				
Segment assets				
a) Manufacturing and trading of Pharmaceutical drugs	886.72	886.24	1,146.53	884.94
b) Consultancy Services	-	12.74	22.47	14.04
Total Assets	886.72	898.98	1,168.99	898.98
Segment liabilities				
a) Manufacturing and trading of Pharmaceutical drugs	8.50	8.55	12.24	8.55
b) Consultancy Services	-	-	-	-
c) Unallocated liabilities	-	-	-	-
Total Liabilities	8.50	8.55	12.24	8.55

2. The above results for the quarter ended 30th June 2023 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.08.2023.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on behalf of the Board

Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 14.08.2023

Decipher Labs Limited (CIN CL23230TG1986PLC006781)

Regd. off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Consolidated Unaudited Financial Results For the Quarter Ended 30 June 2023

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter Ended		Year Ended	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	950.87	977.51	1,261.92	4,557.27
II. Other income	0.50	15.46	686.36	737.06
III. Total revenue (I + II)	951.37	992.97	1,948.28	5,294.33
IV. Expenses				
Purchase of Stock-in-Trade	-	10.35	31.50	47.25
Changes in inventories of finished goods and stock in trade	-	4.42	-	4.42
Employee benefits expense	804.83	683.99	1,063.18	4,119.12
Finance costs	0.52	6.99	11.36	42.69
Depreciation and amortisation expense	11.15	11.99	9.76	42.75
Other expenses	159.79	664.63	241.48	1,229.88
Total expenses	976.29	1,382.37	1,357.28	5,486.11
V. Profit/(Loss) before Exceptional item (III - IV)	(24.92)	(389.40)	591.00	(191.78)
VI. Exceptional items	-	-	-	224.15
VII. Profit/(Loss) after Exceptional item (III - IV)	(24.92)	(389.40)	591.00	(415.93)
VIII. Tax expense:				
(1) Current tax	-	37.52	-	(46.89)
(2) Deferred tax	69.89	(0.03)	0.13	(100.81)
(3) Tax of earlier years	-	-	-	-
IX. Profit/(Loss) for the period (V-VI)	(94.81)	(426.89)	590.87	(268.23)
X. Other comprehensive income				
Items that will be reclassified to statement of profit and loss	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	2.23	(16.02)	57.96	172.57
XI. Total comprehensive income for the year	(92.58)	(442.91)	648.83	(95.66)
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
XI. Earning per equity share				
(1) Basic	(0.94)	(4.23)	5.85	(2.66)
(2) Diluted	(0.94)	(4.23)	5.85	(2.66)

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter Ended		Year Ended	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Audited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	-	16.80	45.00	68.82
b) Consultancy Services	950.87	960.71	1,216.92	4,488.45
Total Sales	950.87	977.51	1,261.92	4,557.27
Less: Inter Segment Revenue	-	-	-	-
Total Revenue from Operations	950.87	977.51	1,261.92	4,557.27
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	(10.55)	2.59	21.48	2.72
b) Consultancy Services	14.89	246.64	580.87	255.66
Total	4.34	249.23	602.35	258.38
Less: Interest	0.52	4.97	11.36	47.66
Total Profit before tax	3.82	244.26	590.99	210.72
Capital employed (Segment assets - segment liabilities)				
Segment assets				
a) Manufacturing and trading of Pharmaceutical drugs	46.72	261.13	306.53	261.13
b) Consultancy Services	2,565.18	3,933.17	3,761.04	3,933.17
Total Assets	2,611.90	4,194.30	4,067.57	4,194.30
Segment liabilities				
a) Manufacturing and trading of Pharmaceutical drugs	8.50	8.17	12.24	8.17
b) Consultancy Services	379.51	1,770.21	990.00	1,770.21
Total Liabilities	388.01	1,778.38	1,002.24	1,778.38

2. The above results for the quarter ended 30 June 2023 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.08.2023.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The above results as of 30.06.2023 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.

5. The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

6. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on behalf of the Board

Sushant Mohan Lal

Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 14.08.2023



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Decipher labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Review Report to
The Board of Directors
Decipher labs Limited.**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (the "Company") for the quarter ended 30th June 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.002934S)

K. Sreenivasan

Partner

Membership No.206421

UDIN: 23206421BGTHQM6250

Place: Secunderabad

Date : 14.08.2023





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Decipher labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited ("the Holding Company") and its subsidiaries, (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2023 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the subsidiaries.
Decipher Software Solutions LLC, USA
Decipher Soft Middle East W.L.L Bahrain
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiary referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Ramanatham & Rao

Chartered Accountants

6. We did not review the interim financial results of one subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total revenue of Rs.950.87 lakhs, total net profit after tax of Rs.(82.59) lakhs and total comprehensive Income of Rs.(82.59) lakhs for the quarter ended 30th June, 2023, as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of this subsidiary is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.002934S)



K.Sreenivasan

Partner

Membership No.206421

UDIN: 23206421BGTHQN1472

Place : Secunderabad

Date : 14.08.2023

